Table 1 MMP2 genotypes vs clinical, pathological and epidemiological variables
Variables | MMP2 | |||||||
|---|---|---|---|---|---|---|---|---|
| Â | -1306 C/T | p-value* | -735 C/T | p-value* | ||||
| Â | CC | CT | TT | Â | CC | CT | TT | Â |
Stage at Diagnosis | Â | Â | Â | Â | Â | Â | Â | Â |
   0 | 34 (59%) | 19 (33%) | 5 (9%) |  | 48 (83%) | 10 (17%) | 0 (0%) |  |
   I | 320 (64%) | 159 (32%) | 23 (5%) |  | 365 (73%) | 123 (25%) | 13 (3%) |  |
   II | 152 (65%) | 72 (31%) | 9 (4%) |  | 184 (78%) | 49 (21%) | 2 (1%) |  |
   III | 105 (63%) | 54 (32%) | 9 (5%) |  | 131 (79%) | 32 (19%) | 3 (2%) |  |
   IV | 6 (67%) | 3 (33%) | 0 (0%) | 0.92 | 4 (44%) | 5 (56%) | 0 (0%) | 0.08 |
Primary Clark Level | Â | Â | Â | Â | Â | Â | Â | Â |
   I | 34 (59%) | 19 (33%) | 5 (9%) |  | 48 (83%) | 10 (17%) | 0 (0%) |  |
   II | 70 (65%) | 36 (33%) | 2 (2%) |  | 79 (74%) | 23 (22%) | 5 (5%) |  |
   III | 89 (60%) | 48 (32%) | 12 (8%) |  | 115 (77%) | 32 (21%) | 3 (2%) |  |
   IV | 308 (64%) | 155 (32%) | 22 (5%) |  | 358 (74%) | 116 (24%) | 10 (2%) |  |
   V | 51 (74%) | 14 (20%) | 4 (6%) | 0.20 | 54 (78%) | 15 (22%) | 0 (0%) | 0.44 |
Thickness (mm) | Â | Â | Â | Â | Â | Â | Â | Â |
   In situ | 34 (59%) | 19 (33%) | 5 (9%) |  | 48 (83%) | 10 (17%) | 0 (0%) |  |
   < 1.01 | 201 (63%) | 107 (33%) | 12 (4%) |  | 237 (74%) | 72 (23%) | 10 (3%) |  |
   1.01 – 2.00 | 174 (64%) | 81 (30%) | 15 (6%) |  | 199 (73%) | 68 (25%) | 4 (2%) |  |
   2.01 – 4.00 | 100 (63%) | 50 (31%) | 10 (6%) |  | 124 (78%) | 33 (21%) | 2 (1%) |  |
   > 4.00 | 81 (68%) | 35 (29%) | 4 (3%) | 0.72 | 94 (78%) | 25 (21%) | 1 (1%) | 0.44 |
TILs | Â | Â | Â | Â | Â | Â | Â | Â |
   Absent | 129 (63%) | 67 (33%) | 9 (4%) |  | 161 (79%) | 40 (20%) | 3 (2%) |  |
   Non-brisk | 262 (67%) | 111 (28%) | 21 (5%) |  | 289 (73%) | 95 (24%) | 10 (3%) |  |
   Brisk | 19 (63%) | 9 (30%) | 2 (7%) | 0.80 | 21 (68%) | 10 (32%) | 0 (0%) | 0.32 |
Distant Metastasis | Â | Â | Â | Â | Â | Â | Â | Â |
   Yes | 86 (67%) | 39 (30%) | 4 (3%) |  | 97 (76%) | 29 (23%) | 2 (2%) |  |
   No | 543 (63%) | 281 (32%) | 42 (5%) | 0.28 | 653 (75%) | 196 (23%) | 17 (2%) | 0.88 |
Intransit Metastasis | Â | Â | Â | Â | Â | Â | Â | Â |
   No | 590 (63%) | 302 (32%) | 46 (5%) |  | 705 (75%) | 216 (23%) | 16 (2%) |  |
   Yes | 18 (67%) | 9 (33%) | 0 (0%) | 0.44 | 22 (82%) | 3 (11%) | 2 (7%) | 0.96 |
Number of Moles | Â | Â | Â | Â | Â | Â | Â | Â |
   None | 161 (62%) | 84 (33%) | 13 (5%) |  | 201 (77%) | 54 (21%) | 5 (2%) |  |
   Few | 311 (63%) | 166 (33%) | 20 (4%) |  | 380 (77%) | 105 (21%) | 11 (2%) |  |
   Moderate | 112 (67%) | 51 (30%) | 5 (3%) |  | 115 (69%) | 49 (30%) | 2 (1%) |  |
   Many | 22 (55%) | 11 (28%) | 7 (18%) | < 0.01 | 29 (73%) | 10 (25%) | 1 (3%) | 0.40 |
Phenotypic Index | Â | Â | Â | Â | Â | Â | Â | Â |
   1 (low risk) | 26 (68%) | 11 (29%) | 1 (3%) |  | 31 (82%) | 6 (16%) | 1 (3%) |  |
   2 | 132 (63%) | 66 (32%) | 11 (5%) |  | 156 (75%) | 47 (23%) | 4 (2%) |  |
   3 | 206 (65%) | 93 (29%) | 18 (6%) |  | 231 (73%) | 76 (24%) | 10 (3%) |  |
   4 | 191 (59%) | 122 (38%) | 11 (3%) |  | 254 (78%) | 68 (21%) | 4 (1%) |  |
   5 (high risk) | 73 (70%) | 27 (26%) | 5 (5%) | 0.28 | 76 (73%) | 28 (27%) | 0 (0%) | 0.36 |